← Back to Search

Neurotoxin

OLD (4 U per 0.1 mL) for Frown Lines

Phase < 1
Waitlist Available
Led By John Joseph, MD
Research Sponsored by Clinical Testing of Beverly Hills
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 18 years of age at the time of signing the informed consent.
Overtly healthy as determined by medical evaluation (includes: medical history, physical examination, and vital signs).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 270 days
Awards & highlights

Study Summary

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Jeuveau in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~270 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 270 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response Duration
Secondary outcome measures
Change from Baseline Score
Change in Frontalis Function
Investigator Live Assessment (At Rest)
+3 more

Trial Design

2Treatment groups
Active Control
Group I: OLD (4 U per 0.1 mL)Active Control1 Intervention
The total Jeuveau dose will be 20U divided into 5 injections. Each subject will receive a total of 0.5 mL of Jeuveau during the treatment.
Group II: COLD (4 U per 0.02 mL group)Active Control1 Intervention
The total Jeuveau dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL of Jeuveau during the treatment.

Find a Location

Who is running the clinical trial?

Clinical Testing of Beverly HillsLead Sponsor
3 Previous Clinical Trials
110 Total Patients Enrolled
Evolus, Inc.Industry Sponsor
7 Previous Clinical Trials
2,489 Total Patients Enrolled
John Joseph, MDPrincipal InvestigatorClinical Testing of Beverly Hills
6 Previous Clinical Trials
168 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
Plastic and Reconstructive SurgeryJournal
Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics
Carruthers, Jean, Steven Fagien, and Seth L. Matarasso. 2004. “Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics”. Plastic and Reconstructive Surgery. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/01.prs.0000144795.76040.d3.
clinicaltrials.govStudy
Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD
2021. "Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05129319.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top